Sophie Chauvet Selected Research

Heme (Haem)

1/2021	Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis.
1/2020	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.
1/2018	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis.
1/2018	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sophie Chauvet Research Topics

Disease

5	Paraproteinemias (Monoclonal Gammopathy) 01/2023 - 06/2015
5	Atypical Hemolytic Uremic Syndrome 01/2022 - 04/2015
4	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 12/2014
4	Proteinuria 01/2019 - 11/2011
3	Neoplasms (Cancer) 01/2024 - 11/2013
3	Kidney Diseases (Kidney Disease) 11/2023 - 11/2015
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2023 - 11/2015
3	Glomerulonephritis 01/2023 - 11/2017
3	Albuminuria 01/2021 - 11/2011
3	Chronic Renal Insufficiency 08/2020 - 12/2014
3	Hemolysis 01/2020 - 01/2018
2	Rare Diseases (Rare Disease) 05/2024 - 10/2022
2	Inflammation (Inflammations) 10/2022 - 01/2018
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022 - 01/2018
2	Lupus Nephritis 01/2019 - 10/2015
1	Bacterial Infections (Bacterial Infection) 02/2024
1	Hemolytic-Uremic Syndrome 02/2024
1	Systemic Scleroderma (Systemic Sclerosis) 02/2024
1	Hematologic Neoplasms (Hematological Malignancy) 02/2024
1	Hereditary Complement Deficiency Diseases 01/2024
1	Thrombotic Microangiopathies 11/2023
1	Primary hyperoxaluria type 1 01/2023
1	Renal Insufficiency (Renal Failure) 10/2022
1	Malignant Hypertension 01/2022
1	Pre-Eclampsia (Preeclampsia) 01/2022
1	Rhabdomyolysis 01/2021
1	Necrosis 01/2020
1	Vasculitis (Vasculitides) 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Immunoglobulin Light-chain Amyloidosis 01/2019
1	Pathologic Processes 01/2018
1	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 11/2017
1	Infections 05/2017
1	Hematuria 11/2015
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2015
1	Kallmann Syndrome (Kallmann's Syndrome) 06/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2014
1	Edema (Dropsy) 12/2014
1	Fibrosis (Cirrhosis) 01/2014
1	Breast Neoplasms (Breast Cancer) 11/2013
1	Neoplasm Metastasis (Metastasis) 11/2013

Drug/Important Bio-Agent (IBA)

15	Complement System Proteins (Complement)IBA 05/2024 - 04/2015
7	Immunoglobulins (Immunoglobulin)IBA 11/2023 - 01/2014
5	Immunoglobulin G (IgG)IBA 01/2023 - 01/2014
4	Heme (Haem)IBA 01/2021 - 01/2018
3	AutoantibodiesIBA 01/2019 - 06/2015
2	Complement C3 Nephritic FactorIBA 10/2022 - 06/2015
2	Complement C3 (C3 Complement)IBA 01/2021 - 04/2015
2	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2021 - 01/2014
2	phenylhydrazine (phenylhydrazine hydrochloride)IBA 01/2020 - 01/2018
2	Complement Factor H (Factor H)IBA 01/2020 - 06/2015
2	LigandsIBA 01/2018 - 11/2013
2	Proteins (Proteins, Gene)FDA Link 11/2015 - 06/2015
2	Semaphorins (Semaphorin)IBA 06/2015 - 11/2013
1	Shiga Toxin (Shigella Toxin)IBA 02/2024
1	Gemcitabine FDA Link 02/2024
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024
1	chemotactic factor inactivatorIBA 11/2023
1	stiripentolIBA 01/2023
1	lumasiranIBA 01/2023
1	OxalatesIBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 10/2022
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 10/2022
1	EnzymesIBA 01/2022
1	HemopexinIBA 01/2021
1	Ifosfamide FDA LinkGeneric 08/2020
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	heme aIBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 01/2018
1	Alternative Pathway Complement C3 ConvertaseIBA 11/2017
1	Immunoglobulin M (IgM)IBA 11/2015
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 06/2015
1	Folic Acid AntagonistsIBA 12/2014
1	Pemetrexed (MTA)FDA Link 12/2014
1	Transferrin (beta 2 Transferrin)IBA 01/2014
1	beta 2-Microglobulin (beta 2 Microglobulin)IBA 01/2014
1	plexinIBA 11/2013
1	Endothelin Receptor AntagonistsIBA 11/2011
1	Angiotensin Receptor AntagonistsIBA 11/2011
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2011

Therapy/Procedure

2	Therapeutics 01/2023 - 01/2022
2	Kidney Transplantation 01/2023 - 12/2019
1	Aftercare (After-Treatment) 01/2024
1	Drug Therapy (Chemotherapy) 01/2020
1	Remission Induction 01/2020